Reference ID: 2968991
Page | 3 . 5.1 Asthma-Related Death [See Boxed Warning] • Data from a large placebo-controlled study in asthma patients showed that long-acting beta
Download Reference ID: 2968991
Information
Domain:
Source:
Link to this page:
Documents from same domain
Effexor (venlafaxine hydrochloride) Tablets …
www.accessdata.fda.govEffexor ® (venlafaxine hydrochloride) Tablets Rx only . Suicidality and Antidepressant Drugs Antidepressants increased the risk compared …
Reference ID: 3101735 - Food and Drug …
www.accessdata.fda.govDocetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
Cytotec® - Food and Drug Administration
www.accessdata.fda.govcytotec® (misoprostol) warnings cytotec (misoprostol) administration to women who are pregnant can cause abortion, premature birth, or birth defects.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govweakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms . FULL …
Namenda XR (memantine hydrochloride) capsules …
www.accessdata.fda.govThe most commonly observed adverse reactions seen in patients administered NAMENDA XR in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the
FOR INTRAVENOUS USE ONLY - Food and Drug …
www.accessdata.fda.govNDA 50-706/S-022 Page 3 MERREM® I.V. (meropenem for injection) FOR INTRAVENOUS USE ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of
NOT FOR USE IN NEONATES CONTAINS BENZYL …
www.accessdata.fda.govDepo-Medrol® methylprednisolone acetate injectable suspension, USP NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL . Not For Intravenous Use . DESCRIPTION
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govDacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and …
Venofer - Food and Drug Administration
www.accessdata.fda.govNDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of …
Diphenhydramine Hydrochloride Injection
www.accessdata.fda.govHOW SUPPLIED Diphenhydramine Hydrochloride Injection, USP is a clear and colorless solution available as: 50 mg/mL in a 1 mL prefilled single-use syringe.
Related documents
Decreased Mortality With Beta-Blockers in Patients With ...
saigaiin.sakura.ne.jpDecreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation An AF-CHF Substudy Julia Cadrin-Tourigny, MD, aAzadeh ...
Effect of age and sex on efficacy and tolerability of β ...
saigaiin.sakura.ne.jpthe bmj | BMJ 2016;353:i1855 | doi: 10.1136/bmj.i1855 RESEARCH 3 Population Individual patient data were available for 18637 patients. For this analysis, restriction to patients with HFrEF was prespecified as a left ventricular ejection
Utilization of Beta Blockers Post-Myocardial Infarction
www.e-mjm.orgbeta blockers during their first MI admission, 4.7% by 6-months and 2.0% by 12-months. Dosage Optimization of Beta-Blocker Therapy The assessment of optimal dosages of beta-blocker therapy
beta-blockers in cardiovascular Medicine
www.japi.orgSUPPLEMENT OF JAPI • dEcEMbEr 2009 • VOL. 57 beta-blockers.
JMCM V9N4 Role of Beta-Blockers for the Post-Myocardial ...
www.namcp.org12 Journal of Managed Care Medicine | Vol. 9, No. 4 | www.namcp.org beta-blockers remain an underutilized therapy in the post-MI period.Physician concerns may exist regarding the safety and benefits of beta-blockers in post-MI